India’s pharmaceutical industry enjoys an enviable reputation globally. According to industry reports, India’s pharmaceutical market is the third largest in the world in terms of volume and thirteenth largest in terms of value. India also leads the world in the manufacturing and export of generic drugs. But, there is significant risk in the Indian business environment regarding non-compliance with the law and in particular the anti-corruption and bribery laws. In a guest article, Shankh Sengupta and Pallav Shukla, partner and associate in Trilegal’s Delhi office, discuss how multinational companies can leverage their anti-corruption compliance programs to help fix this problem, making the pharmaceutical market safer for consumers worldwide. See also “Regional Risk Spotlight: Jay Holtmeier of WilmerHale Explains How to Navigate Bureaucratic Corruption Risks in India” (Sep. 23, 2015).